A new standard is poised to transform melanoma care in terms of both patient outcomes and economics. Results from the phase 3 NADINA trial (Abstract LBA2), presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, showed that a six-week course of neoadjuvant immunotherapy was superior to two years of adjuvant immunotherapy in treating macroscopic, resectable stage III melanoma.
Latest News
Skin cancer the focus of new pharma campaign
While the rates of many cancer types are projected to continue to decrease, melanoma remains a notable outlier. In fact, Merck Canada says the number of Canadians receiving a diagnosis of melanoma each year continues to rise, more than tripling in the past 30 years.
Dr. Farma Discusses Skin Cancer Prevention and Treatment
In an ACS news release, Metropolitan Philadelphia CoC State Chair Jeffrey M. Farma, MD, FACS, recently offered tips for preventing skin cancer and understanding options for treatment.
“Homemade Sunscreen Is Also Homemade Melanoma” — Nara Smith Blasted for DIY Sunblock
It’s no secret that TikTokers have uploaded some objectively stupid content to the platform — like people seemingly blindfolding themselves while driving for the Bird Box challenge.